Medicine and Dentistry
Chronic Kidney Disease
100%
Analysis
46%
Empagliflozin
46%
Kidney
46%
Glomerular Filtration Rate
39%
Patient
39%
Diseases
34%
Urinary System
34%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
32%
Inpatient
29%
Nephropathy
28%
Cardiovascular System
27%
Albumin
25%
Creatinine
25%
Cardiovascular Disease
24%
Kidney Injury
23%
Systematic Review
23%
Dose Response
23%
Biological Marker
23%
Glomerulus
23%
Blood Vessel
23%
Pathologist
23%
Nephrology
23%
Transfer of Learning
23%
Idiopathic Pulmonary Fibrosis
23%
Personalized Medicine
23%
Histopathology
23%
Systolic Blood Pressure
23%
Clinical Research
23%
Intervention Trial
23%
Development
23%
Collaborative Learning
23%
Diuretic Agent
23%
Translational Research
23%
Maturity
23%
Post-Hoc Analysis
23%
Finerenone
23%
Heart Failure with Preserved Ejection Fraction
23%
Peritoneal Dialysis
23%
Experience
23%
COVID-19
23%
Hazard Ratio
14%
Speech-in-Noise Test
13%
Disease Exacerbation
11%
Diabetes
9%
Cotransporter
9%
Acute Kidney Injury
7%
All Cause Mortality
7%
Thiazide Diuretic Agent
7%
Placebo
6%
Albuminuria
6%
Adjustment
6%
Phenotype
5%
Syndrome
5%
Pharmacology, Toxicology and Pharmaceutical Science
Prevalence
25%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
23%
Diabetes Mellitus
23%
Hemodialysis
23%
Cardiovascular Disease
23%
Diuretic Agent
23%
Finerenone
23%
Resistant Hypertension
23%
Kidney Disease
23%
Chronic Kidney Failure
20%
Protein
17%
Interleukin 6
17%
Inflammation
11%
Dose-Response Relationship
11%
End Stage Renal Disease
11%
Cotransporter
6%
Asthma
5%
Renin
5%
Disease
5%
Aldosterone
5%
Chronic Disease
5%
Dialysis
5%
Diabetes Mellitus
5%
Bromocresol Purple
5%
Prevalence
5%
C Reactive Protein
5%
Transferrin
5%
Serum Albumin
5%
Angiotensin
5%
Malnutrition
5%
Neutrophil Gelatinase Associated Lipocalin
5%